H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine
- PMID: 25284811
- DOI: 10.1016/j.vaccine.2014.09.049
H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine
Abstract
Initiation of mass vaccination is critical in response to influenza pandemic. There is an urgent need of a simple, rapid method for production of influenza vaccine that is more effective than current traditional influenza vaccines. Recent H7N9 transmissions to humans in China with high morbidity/mortality initiated extensive vaccine evaluation. We produced the HA1 domains (amino acids 1-320) from H7N9 and H7N7 strains in E. coli. Both were found to contain primarily monomers/trimers with low oligomeric content. However, when residues from the N-terminal β sheet (first 8 amino acid) of H7 HA1 domains were swapped with the corresponding amino acids from H5N1, functional oligomeric H7 HA1 were produced (HA1-DS), demonstrating strong receptor binding and hemagglutination. In rabbits, the HA1-DS from either H7N9 or H7N7 generated high neutralization titers against both homologous and heterologous H7 strains, superior to the unmodified H7 HA1 proteins. In ferrets, HA1-DS from H7N7 elicited higher (and faster) HI titers, better protected ferrets from lethality, weight loss, and reduced viral loads following challenge with wild-type highly pathogenic H7N7 virus compared with inactivated H7N7 subunit vaccine. HA1-DS vaccinated ferrets were also better protected from weight loss after challenge with the heterologous H7N9 virus compared with inactivated H7N7 subunit vaccine. Importantly, the H7N7 HA1-DS vaccine induced antibody affinity maturation far superior to the inactivated H7N7 subunit vaccine, which strongly correlated with control of viral loads in the nasal washes after challenge with either H7N7 or H7N9 strains. We conclude that N-terminus β sheet domain-swap can be used to produce stable functional oligomeric forms of better recombinant HA1 vaccines in simple, inexpensive bacterial system for rapid response to emerging pandemic threat for the global population.
Keywords: Affinity; Antibody; Bacteria; Ferrets; H7N7; H7N9; HA1; Hemagglutinin; Immune Response; Influenza; Pandemic; Vaccine; protein.
Published by Elsevier Ltd.
Similar articles
-
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17. J Virol. 2011. PMID: 21084473 Free PMC article.
-
Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.J Virol. 2017 Sep 27;91(20):e01202-17. doi: 10.1128/JVI.01202-17. Print 2017 Oct 15. J Virol. 2017. PMID: 28768855 Free PMC article.
-
ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.Vaccine. 2015 Jul 31;33(32):3953-62. doi: 10.1016/j.vaccine.2015.06.047. Epub 2015 Jun 17. Vaccine. 2015. PMID: 26093202 Clinical Trial.
-
A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine.Hum Vaccin Immunother. 2020;16(2):286-294. doi: 10.1080/21645515.2019.1649551. Epub 2019 Aug 23. Hum Vaccin Immunother. 2020. PMID: 31419167 Free PMC article.
-
T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response.Hum Vaccin Immunother. 2018;14(9):2203-2207. doi: 10.1080/21645515.2018.1495303. Epub 2018 Sep 5. Hum Vaccin Immunother. 2018. PMID: 30015562 Free PMC article. Review.
Cited by
-
Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.J Virol. 2019 Apr 3;93(8):e00169-19. doi: 10.1128/JVI.00169-19. Print 2019 Apr 15. J Virol. 2019. PMID: 30728266 Free PMC article.
-
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.Lancet Respir Med. 2019 Nov;7(11):951-963. doi: 10.1016/S2213-2600(19)30253-X. Epub 2019 Sep 30. Lancet Respir Med. 2019. PMID: 31582358 Free PMC article. Clinical Trial.
-
How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Expert Rev Vaccines. 2016;15(3):295-311. doi: 10.1586/14760584.2016.1128831. Epub 2016 Jan 6. Expert Rev Vaccines. 2016. PMID: 26641943 Free PMC article. Review.
-
Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients.Nat Commun. 2021 Feb 22;12(1):1221. doi: 10.1038/s41467-021-21463-2. Nat Commun. 2021. PMID: 33619281 Free PMC article.
-
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution.Sci Adv. 2021 Mar 5;7(10):eabf2467. doi: 10.1126/sciadv.abf2467. Print 2021 Mar. Sci Adv. 2021. PMID: 33674317 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials